To the Daily Mail: Congratulations
A few days ago the Daily Mail published an article on the prescription of benzodiazepines. It starts
Countless thousands of Britons have become addicted to pills that have been prescribed by their doctors for pain, anxiety, sleeplessness and depression.
Tranquillisers such as benzodiazepines (also used as muscle relaxants for pain) are highly addictive, yet many medics continue to hand them out for longer than they should.
The article in the Daily Mail prompts me to re-post an item from an old website, actionagainsttranquiliseres.org.uk started in 2003 -but the problem is rather older: The Independent reported in 2010 in Drugs linked to brain damage 30 years ago. Now that’s 37 years ago.
Anyway, here is something from 2003. It’s a submission that a voluntary organisation made to government when there was even less public awareness of the benzo issue. The document was written as background information which in the late ’90s/early 2000s was still very scarce. It was one of several compiled by grassroots organisations intended to inform Government. A Hidden Epidemic was submitted to Home Office Minister Caroline Flint in 2003.
“It is more difficult to withdraw someone from benzodiazepines than it is heroin” “the withdrawal symptoms are so intolerable that people have a great deal of problem coming off”. Lader M.1999
“Most benzodiazepines impair and compromise a wide range of basic skills which are absolutely necessary for coping with the intellectual and psychological demands of everyday living.” Hindmarch I. 1999
Cognitive and other coping mechanisms are vital for negotiating busy streets etc. With these abilities impaired by BZs, many long-term users find themselves increasingly housebound with agoraphobic-type symptoms.
the benzodiazepine tranquillizers and hypnotics, more than double the risk of injurious accidents/ the use of the most frequently prescribed impairing medication, the benzodiazepine tranquillizers and hypnotics, more than double the risk of injurious accidents 32 De Gier 1998/9.
– Increased drug-related deaths
– Risks to the unborn child
– Crime and criminal behaviour
Next time I get a chance, I will ask Caroline Flint whether A Hidden Epidemic got through the departmental filter and she got a chance to read it.
After 37 years it’s good to see the Daily Mail on the case. The problem hasn’t disappeared.
A Hidden Epidemic.
A group of drugs which are responsible for an increase in drug-related deaths and unsafe for use in pregnancy, continue to be prescribed and are now flooding the illicit drugs market.
Benzodiazepines (most tranquillisers and sleeping pills, e.g. Valium, Mogadon, Ativan, Librium etc.), are safe drugs when used short-term and according to the guidelines, but their ‘safe’ image may be their greatest danger.
40 years of benzodiazepine prescribing has brought a catalogue of problems in its wake and these are being compounded by their misuse.
As well as increased drug-related deaths and hazards to the unborn child, the immediate dangers of benzodiazepines include increased road traffic accidents, increased falls in the elderly and involvement in crime and criminal behaviour.
Longer term, benzodiazepines use can cause severe addiction and the deterioration of physical and mental health.
Much has been written, but little done, to address the problem of benzodiazepines, although the cost of not doing so, must outweigh that of tackling the issue.
Most facts about benzodiazepines are available, but have failed to reach public awareness.
The purpose of this document is to bring some of those facts together and highlight what has become, a hidden epidemic.
Incidence of Benzodiazepine use
GLOBAL CONSUMPTION RISING
1.5 MILLION LONG-TERM UK USERS
“You have this huge problem, with a huge number of people involved and yet
we seem as a society to be incapable of acting on it” – Phil Woolas MP, 2000 137
Global benzodiazepine (BZ) consumption rose between 1991 and 2000, with Europe the highest consumer.1
Several European countries report high BZ consumption rates, Ireland being one of the highest. Belgium, Spain and Portugal also have high BZ consumption.2
In Ireland, 10% of all adults take prescribed BZs, 20% of whom are elderly. Of these, 70% are long-term BZ users.3
BZ-related problems are common worldwide and one international study indicates that long-term prescribing is still accepted practice4, for example, in The Netherlands, an estimated 50,000 long-term prescribed BZ users are created annually. 5
“The optimistic idea that chronic benzodiazepine users would soon die out, cannot be confirmed” – Van der Vaals F, 2001 5
In the UK, there are at least 13 million prescriptions for BZs per year, 8 with 1 – 1.5 million people currently taking them. 9
Long-term BZ users
Available figures show at least 1 million people currently on long-term BZ prescriptions (> 4 months) in the UK,10 some of whom have been on their drugs for up to 40 years.
GP practices in the UK average 100 – 200 patients on long-term BZ prescriptions.11A recent audit in one UK health care trust found around 3.5 thousand prescribed BZ users amongst 29 GP practices; (average 125 patients per practice). Of these, almost 70% were long-term BZ users (>2years).
Another UK study estimated that in one District Health Authority, there are an estimated 14 thousand patients on long-term BZ prescriptions (>6 months).12
BZ misuse is widespread. In Hong Kong BZs were rescheduled as a ‘dangerous drug,’ which halved prescribing and their subsequent supply to the illicit market.6 Results from a questionnaire issued by the Pompidou Group in 2001, revealed that no country questioned could provide figures on the prevalence of BZ abuse or their illegal consumption, although all countries agreed that BZs posed a public health hazard. 7
The prevalence of BZ misuse in the UK has been reported by the Department of Health variously, as 16% 15 and 90% 13, 14 for England, 55% 15 for Scotland and 23% 15 for Wales.
- DIFFICULT WITHDRAWAL
- GENERAL HEALTH PROBLEMS
- LONG-TERM PROBLEMS
A short-term drug
Benzodiazepines (BZs) are effective drugs used Short-term, but long-term use brings problems with side effects, dependence and deterioration in health.
In 1988, the Committee on the Safety of Medicines issued guidelines regarding BZs and recommended that they should only be prescribed for 2-4 weeks, due to the risk of dependence. 21
“There is increasing evidence that long-term prescribing of benzodiazepines may cause harm.” SMMGP, 1998. 16
How benzodiazepines ‘work’
A major effect of benzodiazepines (BZs) is the enhancement of the GABA (gamma amino butyric acid) neurotransmitter system present throughout the brain and nervous system. 17
The function of the GABA system is to regulate and ‘damp down’ reactions to stimuli and excitation throughout the system. The enhancement of GABA is why BZs ‘work’ so effectively as tranquillisers and sleeping pills. BZs are also used as anti-epileptics, muscle relaxants and in hospital procedures (where their amnesic qualities/side-effects are an additional benefit). 18
Many BZ side-effects are also their ‘therapeutic’ sedative effects, such as drowsiness, ataxia, fatigue, confusion, weakness, dizziness, vertigo, fainting etc. 19
“Symptoms such as persistent tinnitus, involuntary movements, paraesthesia, perceptual changes, confusion, convulsions, abdominal and muscle cramps, and vomiting may be characteristic of benzodiazepine withdrawal syndrome.” Wyeth Laboratories. 1990 20
Altered brain chemistry
The changes in brain chemistry caused by BZ use become harder to reverse over time, 22increasing the risk of protracted withdrawal syndrome.
“It is more difficult to withdraw someone from benzodiazepines than it is heroin” “the withdrawal symptoms are so intolerable that people have a great deal of problem coming off”. Lader M.1999 23
Dependence on BZs can occur after 3 weeks of continuous use, and after 3 months in nearly half of users. 24 The BZ withdrawal syndrome lasts from four weeks to a year or more 25 (British National Formulary, 2002) and can be severely disabling.
Nervous system effects
Multiple neurological symptoms are associated with BZ use, particularly during withdrawal. These include disturbances of perception, sensation, co-ordination and consciousness.
“Most benzodiazepines impair and compromise a wide range of basic skills which are absolutely necessary for coping with the intellectual and psychological demands of everyday living.” Hindmarch I. 1999 26
A major effect of BZ use, is cognitive impairment, with memory functions such as information processing, specifically impaired.27 Memory “blackouts” are also common; the sufferer may have performed complex tasks such as driving a car but have no recall. 28 The consequences of this impairment can be a deterioration in behaviour and day-to-day functioning, which tends to reverse after withdrawal of BZs. 29, 135.
Cognitive and other coping mechanisms are vital for negotiating busy streets etc. With these abilities impaired by BZs, many long-term users find themselves increasingly housebound with agoraphobic-type symptoms. This has a significant impact on both the sufferer and those around them.
In one study, 20% of long-term BZ users developed incapacitating agoraphobia, which largely disappeared after withdrawal from the drug. 31
the benzodiazepine tranquillizers and hypnotics, more than double the risk of injurious accidents/ the use of the most frequently prescribed impairing medication, the benzodiazepine tranquillizers and hypnotics, more than double the risk of injurious accidents 32 De Gier 1998/9.
Psychomotor impairment caused by BZs increases the risk of falls (particularly in the elderly)33 and road traffic accidents. 32,33
“Striking deterioration in personal care and social interactions has been reported ” [with BZ use]. WHO, 1985 34
Depression, aggression, irritability, mood swings, impaired response to stress, excess anxiety, general dysphoria – all are adverse effects of BZ 18 use and may be mistaken for mental health problems.
“This hatefulness was of a peculiar type. The patients were unhappy with it; they realised that it was unnatural and without basis, but were impotent to do anything about it “Feldman P., 1962. 35
Risk of suicide
An increase in suicidal thoughts and tendencies associated with BZ use has been reported since the early 1960s. 36,37.
General health problems
” even small anatomical, biochemical, or physiological insults to the nervous system may result in adverse effects on human health”. Environmental Protection Agency, 1997 38
Long-term BZ use is associated with an overall deterioration in general health, reflected in increased use of health services 39 and increased prescribing for other health problems.
In 1989, findings from a large UK survey revealed high rates of ill health amongst long-term BZ users. These users were prescribed on average 3 types of other medication. The medications most commonly prescribed were for pain relief, gastrointestinal problems and heart problems.136
In 2001, a report from The Netherlands, reflecting the above, showed long-term BZ users being prescribed twice the amount of medications for other complaints as short-term BZ users. 5
An improvement in general health after withdrawal from BZs reflected in reduced use of health services has been reported. 40
BZ-related problems can manifest in all bodily systems including the endocrine 41 and immune system. 42
“PWS (post withdrawal syndrome) is likely to be a genuine iatrogenic complication of long-term benzodiazpine treatment” Higgitt A, 1990 43
Symptoms persisting long after withdrawal from BZs; a ‘Post-withdrawal syndrome,’ has been identified by several authors, indicating that these symptoms are not a return of the original problem. 43,44.
The drug flumazenil, a BZ antagonist (‘antidote’) has been found to eliminate or reduce many ‘post withdrawal symptoms’. 45,30.
Recovery from BZ withdrawal can continue over months or years in some patients. 39,40. 135.
“repeated insult to the nervous system could lead to an adaptation. There are, however, limits to this capacity, and further exposure could lead to frank manifestations of neurotoxicity at the structural or functional level” Environmental Protection Agency, 1999.38
Reports are increasing in some long-term BZ users of problems consistent with the Environmental Protection Agency’s criteria for functional neurotoxicity listed below: 38
- Alterations in sensations of sight, hearing, or touch;
- Alterations in simple or complex reflexes and motor functions;
- Alterations in cognitive functions such as learning, memory, or attention;
- Changes in mood, such as fear or rage, disorientation as to person, time, or place, or distortions of thinking and feeling.
Adverse effects in somatic/autonomic, sensory, motor and cognitive function, together with measurable alteration in BZ receptor function in the brain, 22 suggest that BZs can cause neurotoxicity with long-term use.
Benzodiazepines in Pregnancy
- DRUG WITHDRAWAL AT BIRTH
- RISK OF COT DEATH
- DEVELOPMENTAL PROBLEMS
- IMPAIRED METABOLISM
“Exposure of our most valuable resource, our children, to harmful developmental effects of drugs is a problem of staggering proportion.” Huestis M. 46
It is accepted that there are dangers to newborn babies exposed to ‘dangerous’ drugs such as alcohol and opiates during pregnancy, but the risks of prescribed drugs during pregnancy are rarely examined. In 1978, the Australian National Drug Information Service stated that benzodiazepines (BZs) were contraindicated during pregnancy. 47
Benzodiazepines are classified by the US Food and Drug Administration (FDA), as pregnancy category ‘D’, 48, 49. which should not normally be taken during pregnancy and category ‘X’,50which should never be taken during pregnancy (opiates are category ‘B’ or ‘C’). *See FDA categories below.
BZs readily cross the placenta reaching high levels in the foetus 51,52 and are also present in breast milk. 53.
Worldwide, an estimated 85% of all psychotropic medicines prescribed to pregnant women are for BZs. 54 The incidence of BZ use during pregnancy is unclear and figures varying from 1-3%, 55 to 40% 56 have been suggested. These figures do not include women who misuse BZs, 90% of whom are of childbearing age 57.
1 in 6 newborn infants
BZs were detected in 18% of infants born between October and November 2000 at a Glasgow maternity hospital 58
“We noted a high rate of prescribing of benzodiazepines to pregnant women in spite of documented evidence that this may lead to the so-called “floppy baby syndrome” of neonatal drowsiness, hypotonia and withdrawal symptoms” O’ Shaughnessy P., IMJ, 1993 59
It is a legal requirement that all prescribed medicines in the UK are dispensed with an attached Patient information leaflet. 60Information leaflets for BZs state that they should not be taken during pregnancy, but not all women receive this warning. Although illegal, some prescriptions are currently issued without leaflets. 61 The Committee on Safety of Medicines issued a reminder warning of the dangers of BZ use in pregnancy in 1997, 53 but prescribing of hypnotics and anxiolytics to women of childbearing age rose between 1994 and 1998 (fig. 1). 62
Dangers at birth
Babies exposed to BZs during pregnancy are at risk of the following:
- Low birth weight. 63
- Breathing difficulties. 64,65
- “Floppy” muscles. 64
- Unstable body temperature. 64
- Alteration in heart rate/function. 51,64
- Altered EEG measurements.66
- Withdrawal syndrome (can be protracted) with irritability, convulsions etc. 64,67
Prenatal BZ exposure can cause toxicity and/or withdrawal effects at birth. Affected babies may need months of treatment, sometimes in special care, 68,69,70 whereas the adverse effects of prenatal opiate exposure lasts 2-4 weeks. 70
Flumazenil, a BZ antagonist (‘antidote’) that can reverse many effects of BZs (licensed for use in surgical procedures and overdose), has been used in emergencies (outside of license) in some BZ-exposed neonates, successfully reversing most of the above adverse effects. 71,72,73,74
Risk of Cot death
“The baby might have died on a postnatal ward of an apnoeic episode had he not been admitted to a special care nursery.” The Lancet, 1977 70
BZs are a risk factor in cot death as they can interfere with breathing regulation 64,65. and the drug can remain active in the baby’s system for long periods. 51,56
No specific investigation appears to have been done into prenatal BZ use and cot death.75 Instances of cot death in BZ-exposed infants have been reported 76,77 and in one study the use of nitrazepam has been implicated in sudden unexpected deaths in children. 78
“Diazepam should be avoided in pregnant or lactating animals in humans, it has been shown to be teratogenic when used during the first trimester of pregnancy. Diazepam crosses the placenta and is present in milk.” Veterinary advice, 2001 89.
Conflicting reports of the incidence of cleft palate and other malformations have continued to emerge since the 1970s; the results remain unclear. A recent meta-analysis (2000) of 13 studies showed no increased risk of BZ-induced malformations from cohort studies and slight increased risk from case-controlled studies. 79
Animal studies show that BZs can interfere with foetal development including neurodevelopment, 17, 80 and development of the immune system. 81,82
Current human research 83,84 reflects many animal findings, as do the growing anecdotal reports.
An informal study amongst self-reported parents of 63 BZ-exposed children 85 revealed high rates of neonatal and later developmental problems; e.g. 30% needed treatment in special care at birth and 31% developed learning difficulties. Unexposed siblings were reported to be unaffected, indicating that further research is needed.
Parenting and the next generation
Cognitive and other health problems due to parental BZ use can impair parenting skills 86 with negative consequences for the children and the family. Research shows a direct link between parental BZ use (mainly maternal), and subsequent BZ use/misuse in their adolescent children. 87,88
Category X benzodiazepines include: Flurazepam, Estazolam, Temazepam, Quazepam, Triazolam
Definition of FDA pregnancy categories: The FDA-assigned pregnancy categories as used in the Drug Formulary:
|FDA Pregnancy Category A
Adequate and well-controlled studies have failed to demonstrate a risk to the fetus in the first trimester of pregnancy (and there is no evidence of risk in later trimesters).FDA Pregnancy Category B
Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.FDA Pregnancy Category C
Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
|FDA Pregnancy Category D
There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.FDA Pregnancy Category X
Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits
- INCREASED DRUG-RELATED DEATHS
- INCREASED RISK TO THE UNBORN CHILD
- HIV INCREASED RISK OF HIV
New problem – Old drug
Harder to withdraw from than heroin, 16 benzodiazepines (BZs) are also more dangerous to the newborn, 90 and can cause more cognitive impairment during use. 91
Largely unrecognised as “dangerous drugs,” the BZ group of drugs have encroached the illicit market, becoming major drugs of misuse worldwide and the low priority given to this problem has compounded it. 92
BZ dependence can underlie many drug misuser’s problems, which may be being wrongly attributed to more notorious ‘hard’ drugs.
High rates of BZ misuse are reported worldwide, but accurate figures are scarce. In a questionnaire on the prevalence of illicit BZ use issued by the Pompidou Group for the Council of Europe, no country questioned could provide accurate figures.7
Diazepam and flunitrazepam are the main BZs abused worldwide, 92 but it has been shown that all BZs have the potential for misuse. When prescription of temazepam was restricted in 1996, misuse of this drug reduced, but there was a corresponding increase in the prescribing and misuse of diazepam. This was reported in both Scotland 93 and North West England. 94
In England, official figures for BZ misuse range from 16% 95 to 90% 13,14 There are probably over 100,000 illicit benzodiazepine abusers in the U.K., and the number is still rising. 96
A ‘secondary’ drug
Misuse of BZs is endemic throujghout the illicit drugs scene, being used mainly as a ‘secondary drug’. 94 BZs are used by drug misusers with alcohol, opiates, methadone, amphetamines, cocaine, and ecstasy, 97 for many reasons, including:
- Low cost on the ‘streets’ (between 50p -Ł1.50 per tablet/capsule) 93
- To ‘tide over’ between doses of primary drug (particularly opiates).97
- To enhance the effect of other drugs, (particularly opiates). 97,98
- To ‘come down’ or ‘chill out’ after amphetamine/cocaine/ecstasy use. 3,98
- To cope with withdrawal symptoms from other, (usually ‘primary’) drugs. 97,98.
- To relieve anxiety and dysphoria due to drug use.97
- To facilitate crime 99,100
- Used alone in high doses to achieve a ‘high’. 3,97
Combined opiate/ benzodiazepine use
“benzodiazepine abuse caused considerable harm among the illegal drug-using population, opiate users suffered the most serious harm.” Department of Health & Children, Ireland, 2002.3
with increased risk of heroin overdose,101 higher levels of HIV risk-talking behaviour, 102poorer physical health and psychological functioning. 103 BZs are used with opiates for several reasons including:
- To ‘ tide over’ between opiate doses or when supplies are scarce. 97
- To enhance the effects of opiates. 97,98
- To relieve opiate withdrawal symptoms. 98,3
Several countries report high levels of BZ/opiate use:
- Geneva: 70% opiate users use BZs 1999) 104
- Toronto: 62.5% of opiate users use BZs 105
- Ireland: 45% of opiate users (1997- ‘8) 99
Injecting drug users
“Benzodiazepine abuse is common among injecting drug users as indicated by studies in Europe, USA, UK, Australia and India and is associated with markedly worse outcomes.” SAHAI Trust, India 108
High rates of BZ use are also common amongst injecting drug users. In Australia for instance, up to 78% of injecting drug users use BZs (2000). 106 In the UK, Up to 49% of attendees at drug misuse centres had injected BZs. 107
Treatment of other addictions with BZs
“Benzodiazepines are a major contributor to drug deaths and are not a safe substitute for methadone.” Keen J., 2001 109
BZs are commonly prescribed to treat addiction to other drugs and alcohol, particularly in combination with methadone, creating further problems and addiction.
In 1988/89, 24.9% of prescribed opiate users in the Northwest of England, used BZs, and 89.6% of those had been prescribed them. 110
BZs are the drug of choice during alcohol withdrawal, but if continued long-term, can cause dependence and compromise therapy due to cognitive side effects. 3 30 – 50% of alcoholics use illicit BZs. 111.
Sources of illicit benzodiazepines
The primary sources of illicit BZs are from legitimate supplies, such as diverted prescriptions, warehouse and pharmacy thefts and prescription forgeries. 92,97.
Problems caused by benzodiazepine misuse
- Increased drug-related deaths
- Risks to the unborn child
- Physical problems
- Social problems
- Psychological problems
- Crime and criminal behaviour
“Polydrug deaths contributed to the overall rise in heroin deaths, especially benzodiazepines.” Keen J. 2001 109
BZs are involved in a large proportion of drug-related deaths. Taken alone in overdose, BZs can cause death, but more commonly, it is their effect in combination with other drugs, which is responsible for most of the deaths.
Children born to benzodiazepine misusers
Over 90% of women attending for drug treatment in the UK are of childbearing age. 112 These children face the same risks as children of prescribed BZ users, but they are compounded by increased dosage and other drug use, particularly opiates; a mixture known to be lethal in adults. 113
An increased incidence of cot death in babies born to opiate users is well established; 114 A risk compounded by the addition of BZs, which can cause multiple problems at birth, including apnoea (stopping breathing). 115
Drug misusers who use BZs have poorer general health, 98 increased incidence of hepatitis C, 116 increased HIV risk-taking behaviour 102 and greater risk of heroin overdose. 101 Where BZs are being injected, BZ users risk venous/arterial damage and amputations. 98
Amnesia, disturbed behaviour, aggression, depression, anxiety and general psychological impairment. 98
Educational failure, unemployment, imprisonment, poor social functioning. 98
BZs are implicated in a wide range of criminal behaviour, due to their behavioural effects, they can induce criminal behaviour in the user and be used against the victim to disable them, e.g. ‘date rape.’ 100 (section 6).
“As in England and Wales, opiates and benzodiazepines were the types of drug most often mentioned on death certificates in recent years” Drugscope Report, 2001 117
In 1999, the Advisory Council on the Misuse of Drugs (ACMD), noted that sub-lethal amounts of BZs and opiates when taken together are a fatal cocktail, acting on different respiratory mechanisms in the brain and that this was responsible for an increase in drug-related deaths. 113
High rates of BZ involvement in drug-related deaths, particularly in combination with opiates are widespread. Fig.1, shows drugs involved in drug-related deaths in Scotland, 1996-2000.118
In England and Wales, similar high rates of BZ involvement in drug-related deaths were recorded, until 1998, when opiate-related deaths escalated and BZ involvement fell (fig.2). 119 The reason for this is not known; possibly, the habits of opiate users in England and Wales differ from those in other countries.
Combined benzodiazepine /opiate-related deaths
In Victoria, New South Wales, BZs were found in 50% of all deaths involving heroin use from 1997 to 2000. 120
A breakdown of the drugs implicated in opiate-related deaths in Dublin City is given in Figure 3. In the years 1998 and 1999, the most common drugs involved in opiate-related deaths were BZs. 121
Crime and Aggression
- INDUCE CRIMINAL BEHAVIOUR
- USED TO FUEL CRIME
- USED AGAINST VICTIMS
- HIGH LEVELS OF USE IN PRISONERS
Benzodiazepines (BZs) can cause violent aggression, memory loss, disinhibition and suggestibility and they are implicated in a wide range of criminal behaviour 123
“The implications of the combination of anti-anxiety agents and aggressiveness are astounding.” Canadian Family Physician, 1975.122
Unlike most other sedatives, BZs alter behaviour and memory without causing loss of consciousness 28 and users can perform complex tasks, but have no recall.27
“Instead of prompting the appearance of delusions and/or hallucinations, many of the patients themselves deliberately used the term “hate”. Feldman P., 1962 35
Violent crimes, including murder, have been attributed to the adverse behavioural effects of BZs. In 1980, a woman who stabbed her husband to death was acquitted, due to the effects of the diazepam that she had been prescribed. 124
“Professor Michael Rawlins said that he believed the tragedy [murder] was probably precipitated by the excessive amount (30mg prescribed diazepam which the defendant had consumed in the preceding twelve-hour period before her husband’s death” Law Society Gazette, 1987. 124
Use of benzodiazepines to perpetrate crime
For ‘Dutch courage’
BZs are used to enhance/fuel the mood of perpetrators of crime, as ‘Dutch courage,’ the loss of inhibition, sedation and disassociation imparting a sense of invulnerability. 99
To incapacitate victims
“As soon as I took the drink- I’d say within three minutes- I didn’t remember anything that happened, until I woke up during the rape.” victim of ‘date rape, 1996 125
BZs are used against the victims of crime such as, physical assaults (indecent assault, rape, incest) and violation of property (swindling, theft etc), 28 as they induce amnesia, disinhibition and suggestibility. 126 Usually the victim’s drink is spiked with a BZ. 125
The amnesia caused by BZs makes it difficult for the victim to recall events, which protects the perpetrator from detection. 28,125
Benzodiazepine use in the prison population
“Benzodiazepines were the commonest drug found by health care staff urine screening new receptions to Swansea” HMIP Swansea Prison,1999.127
High levels of BZ use amongst arrestees and prisoners are common. Figures in the UK range from 13% of arrestees in England and Wales testing positive for BZs (’99-2000) 128 to 45% of prisoners entering Scottish prisons (2000). 129
Many prisoners, typically young prisoners, were coming into the prison with a history of high levels of benzodiazepine use some of whom were the result of GP prescribing.” Chelmsford Prison, 130
Link to violence in inmates
“9 out of 12 suicides at HMP Greenock were connected to heroin or benzodiazepine abuse”. 131
A direct connection between BZ consumption and aggressive behaviour in prison inmates has been reported since the ’70s. High levels of riots, stabbing, cuttings, murders, self-mutilation and attempted suicide in inmates were attributed to BZ consumption in a Utah prison.132
In 1995, clonazepam (a BZ) was restricted by the New South Wales prison service, as it was causing emotionally reactive aggression, self-harm and suicide attempts in inmates. 133
Reduced BZ use – reduced aggression
“the conventional view that symptoms of violent disorders should be tackled by increasing medication has been stood on its head” 134 In 1975, a Canadian prison reported less aggressive incidents on days when inmates were off diazepam medication.122
“81% of inmates involved in aggressive incidents had taken diazepam (Valium) and 3.6 times as many acts of aggression occurred in inmates while on these drugs.”. 122
A study at Parkhurst Special Unit also showed a direct correlation between the reduction of sedative consumption (mainly BZs) by inmates and the reduction of physical assaults from between 1990 and 1995. 134
1. International Narcotics Control Board (INCB), Commentary on global statistics, 2001. 2. Infarmed Instituto Nacional de Farmacia e do medicamentes, Boletim de Farmaco Vigilancia, Vol 5 - No 1- 1st Quarter, 2001. 3. Report of the Benzodiazepine Committee, August 2002, Department of Health and Children, Ireland, August 2002. 4. Ulenhuth E.H., Balter M.B., Ban T.A., Yank K., International Study of Expert Judgement on therapeutic use of benzodiazepines and other psychotropic medications: 1V. Therapeutic dose dependence and abuse liability of benzodiazepines in the long-term treatment of anxiety disorders. Journal of Clinical Psychopharmacology 19 (6 Supplement): 23S-29S, 1999. 5. Van der Vaals F.W. Benzodiazepine use in the Netherlands: changes and hope for the future, The Pompidou Group, Seminar: A contribution to the sensible use of benzodiazepines, Strasbourg, January 2001. 6. Chung K.F., MRCPsych. FHKAM (Psychiatry), Benzodiazepine prescribing trend after its inclusion as a dangerous drug under the Hong Kong Dangerous Drugs Ordinance, HKMJ Vol. 3, No 1, March 1997; 3:16 20. 7. The Pompidou Group, Seminar: A contribution to the sensible use of benzodiazepines, Strasbourg, January 2001. 8. Pharmacy Update, Benzodiazepine Misuse, The College of Pharmacy Practice, Course module 1179,1999. 9. Professor Louis Appleby, National Director for Mental Health, Department of Health: Speaking on Panorama, 13th May 2001 ( transcript). 10. The Tranquilliser Trap, Panorama, BBC1, Sunday May 13th 2001, (Transcript.). 11. Ashton C.H., Benzodiazepine Dependence, School of Neurosciences Division of Psychiatry The Royal Victoria Infirmary, Newcastle Upon Tyne:' Benzodiazepine Dependence', in Cambridge Handbook of Psychology & Medicine, Eds. A Baum, S. Newman, J. Weinman, R. West, C. McManus, Cambridge University Press, 1997, pp. 376-80 12. Private correspondence, 2002. 13. UK Department of Health, Drug Misuse and Dependence: Guidelines on Clinical Management, 1999. 14. Garretty D., Use and Misuse of common benzodiazepines, Leeds Teaching Hospital NHS Trust, Department of Chemical Pathology & Immunology, Leeds UK, NRR Project: D0100651, start date 01.03.94, End date 28.02.97. 15. Department of Health Statistical Bulletin, Statistics from the Regional Drug Misuse Databases for six months ending March 2000. 16. Ford C., Bury J., Reviewing Benzodiazepines Prescribing in General Practice in SMMGP Newsletter number 12, December 1988. 17. Kellogg, Carol K., Neurotransmitters and the Developing Nervous System. Dept. of Brain and Cognitive Sciences, University of Rochester, Rochester, New York, 14627. Selected publication from lab. Monday October 2, 1995. 18. Ashton C.H., 'Benzodiazepines: The still unfinished story', Presentation at the 'Beat the Benzos' conference, Croydon, Nov. 2000. 19. Druginfo, Medscape, 2002: http://www.medscape.com/druginfo/SideEffect?id=1-1615&name;=D IAZEPAM+ORAL&DrugType;=1&MenuID;=ADE&ClassID;=N&GeneralStatemen; t=Y 20. Wyeth Laboratories, ABPI, Product data sheet: lorazepam 1990. 21. Committee on Safety of Medicines, Bulletin to Prescribing Doctors, Current Problems, 1988; Number 21: 1-2, Benzodiazepines, dependence and withdrawal Symptoms. 22. Nutt, D. J., Benzodiazepine Dependence: New Insights from Basic Research. In Benzodiazepines: Current Concepts, Š 1990, John Wiley & Sons LTD. 23. Lader M., BBC Radio 4, Face The Facts, interview with John Waite, broadcast on March 16, 1999 http://www.benzo.org.uk/facefax.htm 24. Kan C.C., Breteler M.H., Zitman F.G., In Acta Psychiatrica Scandinavica 1997; 96: 85-93. 25. British National Formulary (BNF), 4.1, Hypnotics and Anxiolytics, No 43, March 2002. 26. Hindmarch I., Benzodiazepines and their effects, Head of Human Psychopharmacology, Research Unit, University of Surrey, Milford Hospital, Godalming, Surrey. 1997. 27. Lader M., Professor Clinical Psychopharmacology, Editorial, Benzos & Memory Loss: more than just old age, Prescriber, Feb 1992. 28. Jouglard J., Adverse effects of Benzodiazepines (BZDs) with potential social consequences, A contribution to the sensible use of benzodiazepines Seminar, Strasbourg, January 2001. 29. Curran H. Older Adults and Withdrawal from Benzodiazepine Hypnotics in General Practice: effects on cognitive function, sleep, mood and quality of life. NRR Project ID : N0466035576. 30. Saxon L., Hjemdahl P., Hiltunen A.J., Borg S., Effects of Flumazenil in the Treatment of Benzodiazepine Withdrawal - a Double Blind Pilot Study, Department of Clinical Neuroscience, Section of Psychiatry and Psychology, Karolinska Institute, St Görans Hospital. In Springer LINK: Psychopharmacology - abstract Volume 131, issue 2 (1997), pp. 153-160. 31. Ashton C.H., DM, FRCP, Benzodiazepine Withdrawal: Outcome in 50 Patients First published British Journal of Addiction (1987) 82, 655-671. 32. De Gier J.J., Review of European Investigations of Illicit Drug Prevalence in Road Traffic Accidents, Department of Pharmacoepidemiology & Pharmacotherapy, Faculty of Pharmacy, University of Utrecht, PO Box 80082, 3508 TB Utrecht, The Netherlands.(Ca 1998/9). 33. Evans M., Waghorn T., Benzodiazepine Dependence and Withdrawal, GP Drug & Alcohol Supplement No. 9, February 1998, Central Coast Area Health Authority, Australia. 34. WHO Review Group, Use and Abuse of Benzodiazepines, Bulletin of the World Health Organization 1983; 61: 551-562. 35. Feldman P.E., An analysis of the Efficacy of Diazepam. Journal of Neuropsychiatry 1962: 3 (suppl1): 62-67. 36. Ryan H.F., Merritt B., Scott G.E., Krebs R., Thompson B.L., Increase in Suicidal Thoughts and Tendencies: Association with Diazepam Therapy, Denver General Hospital (Ryan H.F, Scott G.E, Krebs R., Thompson B. L.); Mount Airey Hospital (Ryan H.F., Merritt B.); Bethesda Hospital (Ryan H.F.). Reprints: (Dr Ryan), Denver General Hospital, W Sixth Avenue & Cherokee Street, Denver 80204, JAMA, March 25th, 1968. Vol 203, No 13. 37. Hall R.C.W., Joffe J.R., Aberrant Response to Diazepam: A New Syndrome, American Journal of Psychiatry 1972; 129: 738-742. 38. Guidelines for Neurotoxicity Risk Assessment, US Environmental Protection Agency, 1998 EPA/630/R-95/001F Washington DC. Federal Register 63(93): 26926 -26954. 39. K F Chung, R C H Cheung, J W Y Tam Long-term Benzodiazepine Users - Characteristics, Views and Effectiveness of Benzodiazepine Reduction Information Leaflet, in HKMJ, Vol 3 No 1 March 1997 40. Private correspondence, Professor Heather Ashton, 2001. 41. Arvat E., Giordano R., Grottoli S., Ghigo E., Benzodiazepines and Anterior Pituitary Function, Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Turin, Turin Italy. In J. Endocrinol. Invest. 25: 735-747, 2002. 42. Lechin F, van der Dijs B, Vitelli-Flores G, Baez S, Lechin ME, Lechin AE, Orozco B, Rada I, Leon G, Jimenez V., Immunological Parameters in Long-term Benzodiazepine users. Clin Neuropharmacol 1994 Feb; 17(1): 63-72 Section of Psychopharmacology, Central University of Venezuela, Caracas. 43. Higgitt A., Fonagy P., Toone B., Shine P., The Prolonged Benzodiazepine Withdrawal Syndrome: Anxiety or Hysteria ? Acta Psychiatrica Scandinavica 1990; 82: 165-168. 44. Ashton C.H., DM, FRCP., Protracted Withdrawal Syndromes from Benzodiazepines First published: Journal of Substance Abuse Treatment Vol. 8 pp. 19-28 ˇ 1991. 45. Lader M.H., Morton S.V., (1992), 'A Pilot Study of the effects of Flumazenil on symptoms persisting after Benzodiazepine withdrawal', Journal of Psychopharmacology, 6, pp.357-363. 46. Huestis M.A., Drug Abuse's Smallest Victims: In Utero Drug Exposure, Chemistry and Drug Metabolism, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD 21124, USA (email@example.com). 47. Prescription Properties Guide, (Australia), National Drug Information Service Profile: Lorazepam, Editors: Treleaven G.I., Thomas J., Compiled, 1978, Annual Supplement, July 1980. 48. Goff D., MD,, Best Practice of Medicine, Approach to the Patient with Acute Psychosis, Merck Medicus, March 2001. 49. Matteson P. S., Women's Health during the Childbearing Years, A community-based approach., Medications and Drugs Commonly used during Pregnancy.,' Your Premier Health Science Information Source', Elsevier, Mosby inc., Š 2003, affiliate Elsevier USA. 50. Medscape Today, March 6th 2003: New Drugs of 1999, J Am Pharm Assoc 40(2):181-221, 2000. Š 2000 American Pharmaceutical Association. 51. Animal Teratogenicity, Benzodiazepines: Psychopharmacology Bulletin, Vol 23, No 4, 1987. 52. Seibert D., Disclosures, Management of Common illness during Pregnancy, National Conference for Nurse Practitioners, 2001. 53. Committee on Safety of Medicines Bulletin, 1997 Reminder: Avoid benzodiazepines in pregnancy and lactation. 54. Marchetti F, Romero M, Bonati M, Tognoni G, CGDUP. Use of psychotropic drugs during pregnancy. Eur J Clin Pharmacol 1993;45:495-501. 55. Ormond K.E., Guttmacher M.D., Vermont Pregnancy Risk Information Service 1995. 56. Mc Elhatton P.R: The Effects of Benzodiazepine use during pregnancy and Lactation.The Teratology Information Service, The UDMS, St Thomas' Hospital, London. Reproductive Toxicology, Vol 8, No 6 pp. 461 - 475. 1994. 57. Institute for the Study of Drug Addiction (ISDD), Drug situation in the UK - trends and update, 24 .01. 2000. 58. Abd-El-Azzim G.M., Anderson R.A., Jackson L., Sceoch C.H., Williamson S. Survey of Illicit Drug Use During Pregnancy in the Galsgow Area based on Meconium Analysis: Department of Forensic Medicine and Science, University of Glasgow Neonatal Unit, Glasgow Royal Maternity Hospital. 59. Phelan H., O'Saughnessy G., O'Cuill D., Jenkins D.M., Night Sedation in Pregnancy - Inappropriate Prescribing. Irish medical Journal, 1993; 86:107. 60. Council Directive 92/27/EEC of 31 March 1992 on the labelling of medicinal products for human use and on package leaflets, mOfficial Journal L 113 , 30/04/1992 p. 0008 - 0012 61. Consultation letter: MLX 285, Department of Health Medicines Control Agency, Market Towers, 1, Nine Elms Lane, London, SW8 5NQ 1. August 2002. 62. Vital Health Statistics, General Practitioner Database, hypnotic and anxiolytic prescribing, 1994-1998. 63. McCarthy J.E., Siney C. (2), .Shaw N.J., .Ruben S.M., Abstract volume 158, issue 9 (1999) pp748 - 749, European Journal of Pediatrics Neonatology: Outcome Predictors in pregnant Opiate and Poly-drug Users. 64. Weber L.W.D., Benzodiazepines in Pregnancy - Academic Debate or Teratogenetic Risk? Geeleschaft fur Strahlen - und Umveltforschung m.b.H. Munchen, Institut fur Biologie, Abteilung Nuklearbiologie, Ingolstadter Landstresse 1, D-8042 Neuherberg,FRG. 65. Dr A.N.P. Speight, Chilldren's department, Newcastle General Hospital, Newcatle Upon Tyne, NE4 6BE: Floppy Infant Syndrome and Maternal Diazepam and/or Nitrazepam. The Lancet, October 22, 1977. 66. Patrick H. T., Tilstone W.J., and Reavey P., Diazepam and Breastfeeding The Lancet, 1972: i: 542 - 3. 67. Thiels C., Pharmacotherapy of Psychiatric Disorder in Pregnancy and during Breastfeeding: A Review. Department of Neurology, Free University of Berlin (west), Germany. In Pharmacopsychiat. 20 (1987) 133-146. 68. Cochlan D., Milner M., Clarke T., Lambert I., McDermott C., McNally M., Beckett M., Matthews T: Neonatal Abstinence Syndrome, Department of Paediatrics and Obstetrics, Rotunda Hospital, Parnell Square, Dublin 1. Irish Medical Journal, January/February 1999, Volume 92, No http://www.imj.ie/news_detail.php?nNewsId=2071&nVolId;=70 69. Wilbourne P.L., Dorato V., Miller W.R., Curet L.B., Benzodiazepine and Methadone use is associated with Longer Neonatal Withdrawal in Poly-Substance exposed Infants, Department of Psychiatry, University of New Mexico, Albuquerque, NM. In American Journal of Obstet. Gynecol., January 2000; 182 (1 pt 2): S177. 70. Robertson J., Paediatrician, Observations on role of benzodiazepines in babies admitted to SCBU. Special Care Baby Unit, Arrowe Park Hospital, The Wirral, Merseyside, UK, 1996. 71. Shibata T., Kubota N., Yokoyama H., Dept. of Anaesthesia, Tokyo General Hospital, School of Medicine, Kawasaki 211, Japan. Japanese Journal of Anaesthesiology, 1994, Vol /Iss/ pg 43/4 (572 574 ISSN: 0021 - 4892. 72. Stahl M. M .S., Saldeen P., Vinge E., Reversal of fetal benzodiazepine intoxication using Flumazenil. British Journal of Obstetrics and Gyanaecology, Vol 100, Pages 185 - 188. 01 - February, 1993. Case report. 73. Richard P., Autret E., Bardol J., Soyez C., Barbier P., Jonville A .P., Dept. Of Neonatology, Tours Cedex, France, The use of Flumazenil in a neonate. Journal of Toxicology, Clinical Toxicology, Vol 29, Page 137 - 140, March 1991. 74. Cone A. M., Nadel S., Sweeney B., "Flumazenil Reverses Diazepam - Induced Neonatal Apnoea and Hypotonia". Dept. of Anaesthetics, Southampton General Hospital Tremona Road, Southampton, SO9 4XY, England. European Journal of Paediatrics, (152 - No 5, 458 - 59, 1993. 75. Dr Sara Levene MA MRCP FRCPCH, Medical Adviser Foundation of the Study of Sudden Infant Death (FSID), Private correspondence, May, 2000. 76. Rementeria J.L, Bhatt K., Withdrawal symptoms in neonates from intrauterine exposure to diazepam. In J Paediatr 1977; 90: 123-126. 77. Martens P. R., A Sudden Infant Death-Like Syndrome Possibly Induced by a Benzodiazepine in Breast-Feeding. European Journal of Emergency Medicine 1994; 1: 86-87. 78. Shields D., Incidence of Death in Patients with Intractable Epilepsy During Nitrazepam Treatment, UCLA School of Medicine, Los Angeles, California, USA and University of Helsinki for Children and adolescents Neurology & Institute of Occupational health, Helsinki, Finland. Epilepsia, 40(4): 492 - 496 1999. 79. Addis A., Dolovich L.R., Einarson T.R., Koren G., Motherisk, Meta-analysis, Canadian Health Network, March 2000. 80. Grimm V. E., A Review of Diazepam and Other Benzodiazepines in Pregnancy. The Hebrew University of Jerusalem and the Weizmann Institute of Science, Rehovot, Israel. 81. Schlumpf M., et al., Effects of Diazepam on the Developing Immune System. Institute of Pharmacology and Toxicology, University of Zürich. 82. Schlumpf M., Lichtensteiner W., Mechanisms Underlying Developmental Neurotoxicity, Intitute f Pahramcology, University of Zurich, Switzerland in Teratology, 1992 Sep; 46 (3): 35A. 83. Liv Laegried, Gudrun Hagberg and Anita Lundberg. The Effect of Benzodiazepines on the Fetus and the Newborn* Department of Paediatrics 11, Gothenburg University, Gothenburg, Sweden. Received September 11, 1990, accepted September 25 1990. Neuropaediatrics 23 (1992) 18 - 23. 84. Liv. Laegried, Gudrun Hagberg and Anita Lundberg. neurodevelopment in Late Infancy After Prenatal Exposure to Benzodiazepines: A Prospective Study* Received December 21st 1990, accepted January 1991. Department of Paediatrics 11, University of Goteborg, Gothenburg, Sweden. Neuropaediatrics 23 (1992) pp. 60 - 67. 85. Benzact questionnaire, (Informal study) 1997, amongst self-reported parents of BZ exposed children. 86. Robertson J., Paediatrician, Arrowe Park Hospital, The Wirral, Merseyside, UK. Presentation at 'Beat the Benzos' Campaign launch conference, November 2000. http://www.benzact.org.uk/talks.htm 87. Smart RG, Fejer D. Drug Use Among Adolescents and Their Parents: Closing the Generation Gap in Mood Modification Journal of Abnormal Psychology. 1972;79:153-160. 88. Pederson W., Lavik N. J 'Adolescents and benzodiazepines: Prescribed use, medication and intoxication, 1991. 89. Barbara Forney, VMD, Diazepam For Veterinary Use, Wedgwood Pharmacy, 279-C Egg Harbor Road, Sewell, NJ 08080, 1-800-331-8272, Copyright Š 2001-2002. All rights reserved. http://www.wedgewoodpharmacy.com/diazepam.asp 90. Dr James Robertson, Paediatrician, Arrowe Park Hospital, Merseyside: Presentation at ' Beat the Benzos' conference, Croydon, November, 2000. 91. Hendler N., Cinimi C., Ma T., Long D., Cognitive ops: Comparison of Cognitive Impairment due to Benzodiazepines and to Narcotics, in American Journal of Psychiatry, 1980 July: 137 (7):828-30. 92. 1994 Report of the International Narcotics Control Board, United Nations, New York, 1995. 93. Tucker R., 'Jelly Junkies', Benzodiazepines - how they are used, abused and cause dependence, Pharmacy Update, Benzodiazepine misuse, The College of Pharmacy Practice, (Course module 1179), 2000. 94. Drug Misuse in the North West of England, University of Manchester Drug Misuse Research Unit and the Liverpool John Moores University Drugs Monitoring Unit, UK, 1997. 95. Department of Health Statistical Bulletin, Statistics from the Regional Drug Misuse Databases for six months ending March 2000. 96. Ashton C.H., DM, FRCP: Benzodiazepines; the still unfinished story, Presentation at'Beat the Benzos' Conference, Camapign launch, November 1st 2000. 97. Ashton C.H., Benzodiazepine Abuse 2002 First published in Drugs and Dependence, Harwood Academic Publishers (2002)197-212, Routledge, London & New York. 98. Seivewright N., Theory and practice in managing benzodiazepine dependence and misuse, accepted Aug. 1997, in Journal of Substance Misuse (1998) 3, 170-77 Š 1998 Harcourt Brace & co Ltd. 99. Browne R., Sloan D., Fahy S., Keating S., Moran C., O'Connor J: Detection of Benzodiazepine abuse in opiate addicts, The Drug Treatment Centre Board, Trinity Court, 30/31 Pearse Street, Dublin 2.In Irish Medical Journal, January/February 1998, Volume 91, Number 1. 100. Jouglard J., Adverse effects of Benzodiazepines (BZDs) with potential social consequences, A contribution to the sensible use of benzodiazepines Seminar, Strasbourg, The Pompidou Group, January 2001. 101. Evans M., Waghorn T., Benzodiazepine Dependence & Withdrawal, GP Drug and Alcohol Supplement No 9, February 1998, Central Coast Area Health Service, Australia. 102. Klee H., Faugier J., Hayes K., Boulton T., Morris J., AIDS-related risk behaviour, polydrug use and temazepam, Faculty of Community Studies, Manchester Polytechnic, Manchester M13 0JA. & Department of Medical Statisitics, Withington Hospital, Manchester M20 8LR, UK. 103. Darke, Ross, Wickes W., Clifford T: A Pilot Trial of Benzodiazepine Maintenance among High-dose Benzodiazepine Dependent Methadone Patients, NDARC Project, UNSW, Results presented to the National Methadone Conference,Australia, 1998. 104. Broers B., Duboc A.,Meiler A., Marset M: Use and prescription of benzodiazepines among substance abusers in opiate maintenance treatment in Geneva, 2000. a.i.d Berlin Ambulanz fur Integrierte Drogenhilfe in Berlin, a.i.d Neukolln & a.i.d. Kreuzberg. 105. Benedikt Fischer Maritt Kirst, Jürgen Rehm , David Marsh Sue Bondy Mark Tyndall: The Phenomenon of So-called 'Other Drug Use' among Opiate Addicts in the North American Context: Evidence, Consequences, Questions. 106. ACDA: Key Issues Relating to Benzodiazepine Use in Australia, Nov. 1998. 107. Strang J., Griffiths P., Abbey J., Gossop M., `Survey of use of injected benzodiazepines among drug users in Britain.' British Medical Journal 1994; 308: 1082. 108. Kumar S., Reducing harm related to medicinal drugs, Substance Abuse and HIV, SAHAI Trust, 12 Vaidvaram Street, T Nagar, Chennai ( Madras) 600 017, India E-mail: firstname.lastname@example.org 109. Keen Dr J., Drug-related Deaths - How can Primary Care help to reduce them? 6th National Conference, Managing Drug Users in General Practice, Government drugs policy and training -the new agenda for primary care. 10th-11th May Glasgow, Supported by the RCGP, organised by the RCGP HIV working party,2001. 110. Seivewright N., Donmall M.,Daly C., Benzodiazepines in the Illicit Drugs Scene, The UK Picture and some Treatment Dilemmas, Presented at the 2nd International Conference on the Reduction of Drug-related Harm, Barcelona, April 1991. 111. Borg S., Carlsson S., Lafolie P., 'Benzodiazepine /alcohol dependence and abuse', in C.Hallstrom (ed.) Benzodiazepine Dependence. PP. 119-27, Oxford: Oxford Medical Publications. 112. ISDD, Drug situation in the UK - trends and update, 24. 01. 2000. 113. Reducing Drug-related Deaths", Report by the Advisory Council on Misuse of Drugs, 1999. 114. Ward S.L.D., et al., Abnormal Sleeping Patterns in infants of substance Abusing Mothers, American Journal of Diseases of Children, 1987. 115. Weber L.W.D., Benzodiazepines in Pregnancy - Academic Debate or Teratogenetic Risk? Geelescaft fur Strahlen - und Umveltforschung m.b.H. Munchen, Institut fur Biologie, Abteilung Nuklearbiologie,Ingolstadter Landstresse 1, D-8042 Neuherberg,FRG. 116. Bleich A., Gelkopf M., Schmidt V., Hayward R., Bodner G., Adelson M., Correlates of benzodiazepine abuse in methadone maintenance treatment. A one year prospective study in an Israeli clinic. Addiction 94(10): 1533-1540, 1999. (26 refs). 117. Annual Report on the UK Drug Situation 2001, Final version of the 2001 UK Report as submitted to the EMCDDA after consultation with the Hme Office, The Department of Health, The Scottish Executive, The National Assembly for Wales & the Northern Ireland Department of Health & Social Services & Public Safety. 118. General Register Office for Scotland, Occasional Paper, No.5 Published on 18 December 2001 Drug - Related Deaths in Scotland in 2000 G W L Jackson, BSc, MA Statistician, General Register Office for Scotland. 119. Report: Deaths due to drug poisoning: results for England and Wales, 1993 to 2000, Health Statistics Quarterly 13, Spring 2002. 120. Stephen Cordner, Victorian Institute of Forensic Medicine, Cordner's Corner, Volume 6 Issue 1, March 2001 121. Keenan E., Consultant Psychiatrist, An Irish perspective on benzodiazepine prescribing , Report on diazepam in Ireland. Submission to Pompidou Group, A contribution to the sensible use of benzodiazepines, Seminar, Strasbourg, January 2001. 122. Workman D.G., Cunningham D.G., Effect of Psychotropic Drugs in a Prison Setting. A Federal Maximum Security Institution, Canadian Family Physician, November 1975. 123. Lader M., Royal Maudsley Hospital, ISDD, Drug Notes, ŠISDD, 1993. 124. Law Society Gazette, Defendant Acquitted of Murder Due to Excessive Prescriptive Doses of Valium [R v McGuire], Wednesday, 22nd July, 1987.(pp:2/77). 125. Labianca D.A., Rohypnol: Profile of the "Date-Rape Drug," Department of Chemistry, Brooklyn College of the City of New York, Brooklyn, NY11210.2001. 126. Latour J.F., Husson M.C., Escousse A., Fréville C., Fusier I., I. Grenet I., D. Hillaire-Buys D., A. Lillo-Le-Louet A., B. Miquel B., M. Ollagnier M., Pujol M.S., Tollier C., Guillon N : Mini Dossier du CNHIM, Bulletin sur la Medicament Du Centre Hospitalier,d'Information sur le Medicament, CNHIM - Hôpital de Bicętre - 78, rue du Général Leclerc BP 11 - 94 272 Kremlin Bicętre cedex T: +33 (0)1 56 20 25 50 - F. : +33 (0)1 46 72 94 56, Imprimé par b.combrun communication - 14, rue Christine de Pisan - 75 017 Paris. CNHIM 2002 127. HM Chief Inspector of Prisons: Report on full, announced inspection of HM Prison Swansea. 7-16th June 1999. 128. Bennett T., Sibbitt R. (2000), Drug use among arrestees, Home Office Research, Development and Statistics. 129. Scottish Prison Service, October 2000, 364 prisoners (widespread sample from prisons in Scotland) Tested for drugs at entry to prison, 75% tested + for drugs, Drug Misuse in Scotland - statistics 2001. National prevalernce study, CDMR & SCIEH. 130. H.M. Inspectorate of Prisons, Report on an unannounced follow-up inspection of HM Prison Chelmsford, 11-12 April 2000. 131. Assessments. Her Majesty's Chief Inspector of Prisons for Scotland, Report for 1999-2000, 3. Major Custody Issues and General assessments. 132. Brown C.R., The Use of Benzodiazepines in Prison Populations: Journal of Clinical Psychiatry 1978; 39: 219-222. 133. Corrections Health Service: At risk Behaviour associated with Clonazepam, Achieving Excellence in Health Care, Annual Report, New South Wales 1995 - '96. 134. Johnson R., MRC Psych, MRCGP, Levels of Violence and Medication in a Special Prison Unit, 1986-1995. 135. Borg S., Head of Addiction Medicine, Karolinska Institute, Sweden: Neurobiological and structural changes in benzodiazepine users, Presentation 'Beat the Benzos' conference, November 2000. 136. Ashton H.C., Golding J., Tranquillisers: Prevalence, predictors and possible consequences: Data from a large United Kingdom survey, Br J Addict. 1989; 84:541-46 137. Phil Woolas MP., (Oldham East & Saddleworth), Chairman of 'Beat the Benzos' Campaign, opening speech, 'Beat the Benzos' campaign launch, Croydon, November 2000.
TrackBack URL :